Latest News

Category: News

See all

Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery

ASX, News,

Telix and Paris-based Mauna Kea Technologies, today announce an expansion of the IRiS (Imaging and Robotics in Surgery) Alliance through a strategic €6.0 million (AU$9.6 million) investment to develop new hybrid pharmaceutical-device products through the combination of Telix’s cancer-targeting agents with Mauna Kea’s Cellvizio® surgical endomicroscopy platform. Telix’s investment in Mauna Kea will further support the development of advanced imaging...

Read more

First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

ASX, Clinical, News,

Telix today announces that the first patient has been dosed in the Company’s Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen (PSMA) targeting radio-antibody drug conjugate (rADC)...

Read more

Telix to Present at Jefferies London Healthcare Conference 2023

News,

Telix today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies London Healthcare Conference...

Read more

Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region

ASX, News,

Telix today announces it has signed an exclusive agreement with Denmark-based WIIK Pharma ApS (Wiik Pharma) for the distribution of Telix’s investigational prostate cancer imaging agent, Illuccix® (TLX591-CDx, Kit for...

Read more

Telix Completes Acquisition of Lightpoint Medical

ASX, News,

Telix, today announces the completion of the acquisition of Lightpoint Medical and its SENSEI® radio-guided surgery business (refer to announcement on 21 June...

Read more

ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability

ASX, Clinical, News,

Telix today announces positive preliminary results from the Phase I ProstACT SELECT study of its rADC therapy candidate TLX591 (Lutetium (177Lu) rosopatamab tetraxetan) for prostate-specific membrane antigen (PSMA) positive metastatic...

Read more

Activities Report and Appendix 4C for the quarter ended 30 September 2023

ASX, News,

Telix today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 September 2023 (Q3 2023). All figures are in AUD$ unless otherwise...

Read more

Telix Quarterly Results and Investor Call / Webcast Notification

ASX, News,

Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 30 September 2023 on Wednesday 18 October...

Read more

HRH Princess Astrid of Belgium visits Telix’s New European Manufacturing Facility in Brussels South

News,

Telix has welcomed Her Royal Highness, Princess Astrid, Princess of Belgium to Telix Manufacturing Solutions (TMS), the Company’s recently inaugurated production facility, in Brussels South (Seneffe) in the Wallonia region...

Read more

Telix collaborates with Eckert & Ziegler and RefleXion Medical to Expand Treatment Options for Prostate Cancer Patients

News,

Telix, Eckert & Ziegler, and RefleXion Medical today announced a comprehensive collaboration agreement to jointly develop a new concept – Satellite Hot Labs (SHLs). SHLs are designed specifically for radiolabeling,...

Read more